The Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). This open-access, peer-reviewed journal encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical application. Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for ImmunoTherapy of Cancer, an outlet devoted to and created by today's leaders in the field.
Less than a year after its first issue, Journal for ImmunoTherapy of Cancer was accepted to PubMed and PubMed Central! This is an exciting step in the evolution of JITC as it now offers greater visibility and accessibility to all articles accepted to JITC – the only journal specifically focused on all aspects of tumor immunology and cancer immunotherapy.
As a way to say thank you to the dedicated Society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer Society members waived article processing charges for manuscripts accepted before the end of 2014. To take advantage of this member benefit, please call (+414-271-2456) or email (email@example.com) the SITC executive office for your member code.
SITC awarded two, $1,000 USD awards for papers published in JITC by SITC members. Awards were selected by the JITC editorial board and included:
Winners were announced at SITC's 29th Annual Meeting Award Ceremony on Saturday, November 8, 2014. Congratulations!
JITC Best Basic Science Paper Award:
Stefani Spranger, PhD
University of Chicago
"Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment"
JITC Best Clinical Application Paper Award:
Shailender Bhatia, MD
University of Washington
"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase I/II study"
The journal welcomes submissions in the following areas and other related topics:
Basic Tumor Immunology
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune response, oncolytic viruses
Reporting unusual or unexpected clinical cases that expand the field of general medical knowledge
Clinical/Translational Cancer Immunotherapy
First in man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, updates on clinical trials
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies
Triggering discussion on hot topics and innovative concepts
The Editorial Board is comprised of internationally recognized thought leaders in the field and experts in their content areas. They are also members of SITC and deeply committed to advancing the knowledge about, and integration of, cancer immunotherapy research into the clinical setting.
To see a full listing of the JITC Editorial Board, please click here.